Sehn, L. H. Et Al. 2018. Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL.. JOURNAL OF CLINICAL ONCOLOGY , vol.36, no.15 .

Sehn, L. H., Kamdar, M., Herrera, A. F., McMillan, A., Flowers, C., Kim, W. S., ... Kim, T. M.(2018). Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL.. JOURNAL OF CLINICAL ONCOLOGY , vol.36, no.15.

Sehn, Laurie Et Al. "Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL.," JOURNAL OF CLINICAL ONCOLOGY , vol.36, no.15, 2018

Sehn, Laurie H. Et Al. "Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL.." JOURNAL OF CLINICAL ONCOLOGY , vol.36, no.15, 2018

Sehn, L. H. Et Al. (2018) . "Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL.." JOURNAL OF CLINICAL ONCOLOGY , vol.36, no.15.

@article{article, author={Laurie Helen Sehn Et Al. }, title={Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL.}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2018}